Abexinostat
- Generic Name
- Abexinostat
- Brand Names
- -
- Drug Type
- Small Molecule
- Chemical Formula
- C21H23N3O5
- CAS Number
- 783355-60-2
- Unique Ingredient Identifier
- IYO470654U
- Background
Abexinostat has been used in trials studying the treatment of Sarcoma, Lymphoma, Leukemia, Lymphocytic, and Hodgkin Disease, among others. It is a novel, broad-spectrum hydroxamic acid-based inhibitor of histone deacetylase (HDAC) with potential antineoplastic activity.
- Associated Conditions
- -
- Associated Therapies
- -
Follicular Lymphoma Clinical Trial Pipeline Appears Robust With 50+ Key Pharma
DelveInsight's follicular lymphoma pipeline report highlights 50+ companies developing 55+ therapies, including key players like Chia Tai Tianqing Pharmaceutical Group, Incyte Corporation, and others. Promising therapies such as Parsaclisib, TQ-B3525, and Tafasitamab are in various clinical trial phases. Notable events include Incyte's acquisition of tafasitamab rights and Janssen's collaboration with CBMG for CAR-T therapies.
Research study explores targeted therapy for recurrent high-grade glioma
Researchers combine abexinostat (HDAC inhibitor) with temozolomide in a phase 1 trial to treat recurrent high-grade glioma, aiming to find the maximum-tolerated dose and assess efficacy. The targeted therapy could reduce side effects compared to traditional chemotherapies, with potential for fast-tracking due to prior lymphoma studies.
Related Clinical Trials:
Mantle Cell Lymphoma Clinical Trial Pipeline Insights Featuring 20+ Companies
Mantle cell lymphoma (MCL) treatment outcomes improve with novel targeted therapies like BTK inhibitors. DelveInsight's 'Mantle Cell Lymphoma Pipeline Insight 2024' covers 20+ companies developing 22+ therapies, including Venetoclax and ADI-001. Key events include AstraZeneca's Phase III ECHO trial and BeiGene's AACR presentation.
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.
© Copyright 2024. All Rights Reserved by MedPath